Blueprint Medicines Corp Stock Technical Analysis

BPMC Stock  USD 94.86  0.07  0.07%   
As of the 29th of March, Blueprint Medicines shows the Risk Adjusted Performance of 0.034, mean deviation of 2.39, and Downside Deviation of 3.02. Blueprint Medicines Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Blueprint Medicines Corp, which can be compared to its rivals. Please confirm Blueprint Medicines Corp treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Blueprint Medicines Corp is priced correctly, providing market reflects its regular price of 94.86 per share. Given that Blueprint Medicines has jensen alpha of (0.24), we suggest you to validate Blueprint Medicines Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Blueprint Medicines Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Blueprint, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to Blueprint
  
Blueprint Medicines' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Blueprint Medicines Analyst Consensus

Target PriceAdvice# of Analysts
74.65Buy17Odds
Blueprint Medicines Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Blueprint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Blueprint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Blueprint Medicines Corp, talking to its executives and customers, or listening to Blueprint conference calls.
Blueprint Analyst Advice Details
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Blueprint Medicines technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Blueprint Medicines trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Blueprint Medicines Corp Technical Analysis

Indicator
Time Period
Execute Indicator
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Blueprint Medicines Corp volatility. High ATR values indicate high volatility, and low values indicate low volatility.

Blueprint Medicines Corp Trend Analysis

Use this graph to draw trend lines for Blueprint Medicines Corp. You can use it to identify possible trend reversals for Blueprint Medicines as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Blueprint Medicines price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.

Blueprint Medicines Best Fit Change Line

The following chart estimates an ordinary least squares regression model for Blueprint Medicines Corp applied against its price change over selected period. The best fit line has a slop of   0.19  , which means Blueprint Medicines Corp will continue generating value for investors. It has 122 observation points and a regression sum of squares at 1321.85, which is the sum of squared deviations for the predicted Blueprint Medicines price change compared to its average price change.

About Blueprint Medicines Technical Analysis

The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Blueprint Medicines Corp on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Blueprint Medicines Corp based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Blueprint Medicines Corp price pattern first instead of the macroeconomic environment surrounding Blueprint Medicines Corp. By analyzing Blueprint Medicines's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Blueprint Medicines's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Blueprint Medicines specific price patterns or momentum indicators. Please read more on our technical analysis page.
 2023 2024 (projected)
Dividend Yield0.0016659.58E-4
Price To Sales Ratio22.421.28

Blueprint Medicines March 29, 2024 Technical Indicators

Most technical analysis of Blueprint help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Blueprint from various momentum indicators to cycle indicators. When you analyze Blueprint charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Blueprint Medicines March 29, 2024 Daily Trend Indicators

Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Blueprint stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Blueprint Stock analysis

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bonds Directory
Find actively traded corporate debentures issued by US companies
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.37)
Revenue Per Share
4.118
Quarterly Revenue Growth
0.855
Return On Assets
(0.25)
Return On Equity
(1.57)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.